Thomas joined VantagePoint in 2004 focusing on biopharmaceutical and medical device investments. He currently has a primary emphasis in the areas of biofuels and biomaterials. Prior to VantagePoint, he was an Analyst with CDP Capital Technology Ventures, where he developed new fields of investment in the areas of diabetes and metabolic diseases. Earlier in his career, Thomas served as Project Manager for Genopole®, a business incubator specializing in the development of biology on a large scale and the creation of biotechnology companies responsible for conducting technical and economic feasibility studies. Thomas graduated from the University of London. He holds a Ph.D. in Biochemistry and Molecular Biology from University College London and a B.Sc. in Biochemistry from University Paris XI, Orsay.